ArticleTranslational lung cancer research2026
Impact of effective dose to immune cells (EDIC) on survival in limited-stage small cell lung cancer treated with radiotherapy and immunotherapy.
Article in Translational lung cancer research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Concurrent chemoradiotherapy-immunotherapy is promising for limited-stage small cell lung cancer (LS-SCLC), but biomarkers integrating local and systemic immunity are needed. This study evaluates the prognostic value of combining effective dose to immune cells (EDIC) with hematological indicators in these patients. Methods: In this retrospective cohort study of 174 LS-SCLC patients receiving radiotherapy-immunotherapy, we collected clinical data, pre-radiotherapy hematological indices, and dosimetric parameters. EDIC was calculated using an established model. Prognostic cutoffs were determined by receiver operating characteristic (ROC) analysis, and survival outcomes were assessed via Kaplan-Meier and Cox regression methods. Results: ROC analysis established prognostic cutoffs for EDIC and hematological indices. EDIC demonstrated the highest predictive efficacy [progression-free survival (PFS)-area under the curve (AUC): 0.681; overall survival (OS)-AUC: 0.731], followed by platelet-to-lymphocyte ratio (PLR) among hematological markers (PFS-AUC: 0.659; OS-AUC: 0.630). The combination of EDIC and PLR significantly outperformed either marker alone. Survival analysis revealed that the low EDIC group had significantly better median PFS (not reached Conclusions: Our findings demonstrate that a risk stratification model integrating EDIC and PLR effectively discriminates prognostic outcomes in LS-SCLC patients receiving combined radiotherapy and immunotherapy, with low EDIC and low PLR correlating with superior survival.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.